Member Info for bbrq648

As per Prof Carl Smythe, the Schedule of Clinical Testing is on target.
So, we can expect a positive outcome RNS before or by end of this month.

All genuine investors, please don’t post anymore regarding this “Salvadori” and wasting your valuable time.
Just filter him and raise a concern to the LSE to ban him from posting.
Thanks,
bbrq648

Hi StarKnight,
In my last post, I have stated the final dividend as 14.97p per share and after share consolidation this dividend will be 1.5 x 14.97p = 22.46p.

Furthermore, all the 422m shareholders will receive special dividend of £3.55 prior to consolidation.
See the news attached below:
++++++++++++++++++
Pennon also announced a GBP1.5 billion special dividend and GBP400 million share buyback programme.

The special dividend will be worth 355p per share after a two-for-three share consolidation announced Thursday.

In addition, Pennon will pay a final dividend of 22.46p per share, bringing the full-year total to 32.61p per share, after taking account of the share consolidation.

Pennon expects to increase its dividend base by 2p per share in its 2022 financial year to recognise the earnings accretion of the Bristol Water acquisition.
++++++++++++++
Hope this helps.
bbrq648

StarKnight,
Your explanation is correct with respect to the special dividends.
After share consolidation of 3 shares to 2 shares, there is an additional final dividends of 14.97p per share if you hold until another month till the ex-dividend date.

bbrq648

.

Salvadori,
Go and invest in ODX, and that is your normal BB.
Your 3 posts in BRH BB are targeted to identify you as a troll and deramper trying to spread rumours and posting false negatives information.

bbrq648

Buy volumes outweighing sales by approximately seven times this morning.
Good start for the day and will wait and see if it can break 50p today.
Let us wait and see by COB today.

No change in my opinion, and is a strong buy.
Time to top-up or average down.
Have a nice weekend and Bank holiday Monday.
See you all on late Monday night or early morning on Tuesday.

bbrq648

RIO2020,
The spread of Indian mutation B.1.617.2 viruses indicates that the current upstream test and in country testing are failing to isolate person with Indian mutation. Also, this may be failure to identify asymptomatic and pre-symptomatic travellers.

BRH/ Paraytec Testing will be the way forward to identify and isolate pre-symptomatic and asymptomatic people not only travellers.

Blubay,
Welcome.
Your first post here.

Just topped-up 20306 BRH shares@42.35p.
Time to buy BRH and include in your portfolio.
This is based on the latest RNS dated 04-May-2021 that BRH/Paraytec are open to JV/ License/ Takeover discussions.
DYOR

This is the time to buy BRH shares and add to your portfolio.
As per latest RNS dated 04-May-2021, BRH/ Paraytec are ready to started negotiations and share Covid-19 test data.
Expectation of RNS at anytime soon regarding further details.

The spread of Indian mutation B.1.617.2 viruses indicates that the current upstream test and in country testing are failing to isolate person with Indian mutation. Also, this may be failure to identify asymptomatic and pre-symptomatic travellers.

BRH/ Paraytec Testing will be the way forward to identify and isolate pre-symptomatic and asymptomatic people not only travellers.

bbrq648

Derampers and trolls have posted 14 out of last 20 posts.
Purposefully trying to deramping and posting rumours.

BRH RNS, dated 04-May-2021, Paraytec is seeking partners for the commercialisation of its COVID-19 test technology. Hence, BRH would be open to consider a wide range of possible routes, including: JV, licence or acquisition.

Let us, the shareholders wait to hear soon from the BODs on which way the BRH BODs want to move forward. In parallel, additional clinical validation tests are continuing to get a better statistical representation.
This is a golden buying opportunity to either top-up or average down.
Lots of things happening within BRH. Expect very good dividends if any of JV and Licensing happens. If take over, even better.
Don’t sell cheap.

bbrq648

BRH RNS, dated 04-May-2021, Paraytec is seeking partners for the commercialisation of its COVID-19 test technology. Hence, BRH would be open to consider a wide range of possible routes, including: JV, licence or acquisition.

Let us, the shareholders wait to hear soon from the BODs on which way the BRH BODs want to move forward. In parallel, additional clinical validation tests are continuing to get a better statistical representation.

The share value have nearly bottomed, and is a good buying opportunity to either top-up or average down.

The BRH BB welcome Dr Susan (Sue) Anne Hagan as a Non-Executive Director to the Board.

The BRH Shareholders welcome Dr Susan (Sue) Anne Hagan as a Non-Executive Director to the Board.

.

Just topped up £5000 worth of 11190 shares @44.9p